2C-T-22

2C-T-22, also known as 4-(2,2,2-trifluoroethylthio)-2,5-dimethoxyphenethylamine or as 2C-T-TFE, is a psychedelic drug of the phenethylamine, 2C, and 2C-T-x families. https://erowid.org/library/books_online/pihkal/pihkal049.shtml It is closely related to 2C-T-21 (the 4-(2-fluoroethylthio) analogue and 2C-T-21.5 (the 4-(2,2-difluoroethylthio) analogue).

Use and effects 2C-T-22 was briefly described by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in the 2C-T-21 entry, but Shulgin only partially completed the chemical synthesis of 2C-T-22 and did not test it. Subsequently, Daniel Trachsel completed the synthesis of 2C-T-22 and defined its dose as greater than 10mg orally and its duration as approximately 6hours. A total dose of 5mg plus 5mg plus 6mg produced the first signs of effects, but higher doses were not explored. Hence, its precise dose range remains unknown.

Interactions

Pharmacology Pharmacodynamics 2C-T-22 shows affinity for the serotonin 5-HT2A receptor (Ki = 16–102nM) and the serotonin 5-HT2C receptor (Ki = 28–151nM). It has been found to be a potent partial agonist of the serotonin 5-HT2A and 5-HT2B receptors. Other receptor and target interactions have also been described.

History 2C-T-22 was first described in the scientific literature by Shulgin in his book PiHKAL in 1991. Subsequently, Trachsel described and completed the synthesis of 2C-T-22 in 2003 and he and his colleagues defined its properties in humans in 2013.

Society and culture Legal status Canada 2C-T-22 is a controlled substance in Canada under phenethylamine blanket-ban language.

2C-T-22

Bron en licentie